The U.S. Food and Drug Administration has approved Axsome Therapeutics’ Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults.
This article was originally published on MedicalXpress.com
FDA approves Symbravo for acute treatment of migraine in adults
You may also be interested in:
The Latest
Why you should stop buying vitamins and get more sleep instead
Almost half of all Canadians regularly take at least one nutritional supplement such as vitamins, minerals, fibre supplements, antacids and fish oils. Many of these individuals are healthy and hoping to improve general well-being or prevent chronic […]
The Latest
5 Popular Supplements in Canada for Optimal Health and Wellness
As a health and wellness enthusiast, I have always been interested in the role of supplements in promoting optimal health. In Canada, there are many supplements available on the market, each with different benefits and […]
The Latest
Exploring Attachment Styles and How They Affect Adult Relationships
Do you want to know more about attachment types and adult relationships? If so, you’ve come to the right place! In this blog, we’ll examine how different attachment styles impact our relationships and how understanding […]
Read More:
-
Learning French while also developing language skills in one’s mother tongue is no easy task. As a result, allophone children often face learning and communication [...]
-
People who develop multiple sclerosis (MS) as children and grow up in less advantaged neighborhoods may have a larger volume of inflammation and brain tissue [...]
-
Children of mothers who took certain antiseizure medications while pregnant do not have worse neurodevelopmental outcomes at age 6, according to a long-running study. The [...]
